Intravenous immunoglobulin for cystic fibrosis lung disease: a case series of 16 children

I M Balfour-Lynn, U Mohan, A Bush and M Rosenthal

Arch. Dis. Child. 2004;89;315-319
doi:10.1136/adc.2003.026575

Updated information and services can be found at:
http://adc.bmj.com/cgi/content/full/89/4/315

These include:

References
This article cites 20 articles, 5 of which can be accessed free at:
http://adc.bmj.com/cgi/content/full/89/4/315#BIBL

3 online articles that cite this article can be accessed at:
http://adc.bmj.com/cgi/content/full/89/4/315#otherarticles

Rapid responses
You can respond to this article at:
http://adc.bmj.com/cgi/eletter-submit/89/4/315

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Notes

To order reprints of this article go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to Archives of Disease in Childhood go to:
http://journals.bmj.com/subscriptions/
Intravenous immunoglobulin for cystic fibrosis lung disease: a case series of 16 children

I M Balfour-Lynn, U Mohan, A Bush, M Rosenthal


Background and objective: Some children with severe cystic fibrosis (CF) lung disease develop chest tightness, recurrent dry cough, and intractable wheeze, often accompanied by deteriorating lung function and failure to expectorate sputum. In an attempt to reduce the use of regular oral corticosteroids, we treated a group of such children with monthly courses of intravenous immunoglobulin (IVIG).

Methods: This is a retrospective case note review of 16 children, aged 3–16 years (median 13.0 years) who received 1–66 (median 7.5) courses of monthly IVIG, at a dose of 1 g/kg on two successive days for the first dose, followed by 1 g/kg monthly as a 12 hour infusion, with corticosteroid and antihistamine cover.

Results: FEV₁ improved from a median (95% confidence interval (CI)) of 50% (39 to 61%) to 54% (48 to 66%), with a median (95% CI) difference of +7.5% (−1.5 to 14.5%); NS. FVC improved from 65% (60 to 77%) to 83% (70 to 89%), with a difference of +13% (4 to 22%, p = 0.01). The total daily dose/kg body weight of oral prednisolone was reduced from 0.6 (0.3 to 1.0) to 0 (0 to 0.1) mg/kg/day, with a reduction of −0.6 (−1.0 to −0.1, p = 0.006) mg/kg/day. The total daily dose of inhaled corticosteroid (budesonide equivalent) was a median (range) of 2000 µg (800–6000 µg), which was reduced to 1500 µg (0–3200 µg). The median (95% CI) difference was −400 µg (−1600 to 0 µg), p = 0.05. IVIG was well tolerated and the regimen acceptable to all but one of the children. The following transient adverse reactions were seen in only one patient each: headache, fever, hypotension, aspecific meningitis, and chest tightness.

Conclusion: We suggest that an n = 1 trial of IVIG in carefully selected patients with severe obstructive CF lung disease is worth considering, as for some it may lead to significant benefit.

METHODS

This is a retrospective case note review of all children with CF who have received IVIG since 1994, in a single tertiary paediatric CF centre with a clinic population of 350 children.

Administration of IVIG

Criteria for starting IVIG were significant symptoms of airway obstruction (for example intractable wheeze, tight chest, nonproductive cough), with a need for continuing oral corticosteroids or a poor response to corticosteroids. The intended IVIG course was six doses but the decision when to stop was made by one of the consultants on the basis of clinical response (or lack of it), and acceptability to the patients. Patients received IVIG at 1 g/kg on two successive days for the first dose followed by 1 g/kg monthly as a 12 hour infusion, usually given overnight. The children received cover with corticosteroid (intravenous hydrocortisone 4 mg/kg) and antihistamine (intravenous chlorpheniramine 2–4 mg) prior to the infusion starting. Sandoglobulin® (Novartis, Frimley, UK) was used for the first 6 years in the clinic then Flebogamma® (Grifols UK Ltd, Cambridge, UK) after this. The change in product was caused by supply

Abbreviations: ABPA, allergic bronchopulmonary aspergillosis; CF, cystic fibrosis; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroids; IVIG, intravenous immunoglobulin
problems from Novartis. Both IVIG preparations are normal human immunoglobulin in the form of a polyvalent antibody preparation in 0.9% saline.

Lung function
FEV₁ and forced vital capacity (FVC) were recorded as the percentage predicted for sex and height. Small airways function was not recorded owing to the inherent variability of such measurements.

Assessment of therapeutic success
An adequate response to treatment was defined as an improvement in reported symptoms (wheeze, chest tightness, cough), or a clinically significant improvement in lung function (FEV₁ >10%), or a reduction in oral steroid dosage with no worsening in the above two parameters.

Statistical analysis
Statistical analysis was performed using Minitab software (Minitab Inc, State College, PA, USA). Non-parametric Wilcoxon tests were used to compare lung function (FEV₁ and FVC) and inhaled/oral corticosteroid total daily dose at the start and end of the courses of IVIG. Mann Whitney U tests were performed to compare differences in outcomes between different groups (high v low serum IgE, ABPA v non-ABPA). Analysis was performed only on those patients who had received more than one dose of IVIG (n = 15). Values of p < 0.05 were considered statistically significant.

RESULTS
Since 1994, 16 children have been given 1–66 (median 7.5) courses of IVIG, with three children receiving it for more than 1 year (fig 2, table 1).

Baseline characteristics
There were nine girls and seven boys, aged 3–16 years (median 13.0 years). Eleven patients had chronic infection with Pseudomonas aeruginosa, while two were infected with Staphylococcus aureus. Ten patients had been diagnosed with ABPA in the past using the standard criteria, of whom six had active ABPA at the time of starting IVIG (determined by continued symptoms with a high total serum IgE and high aspergillus specific IgE). Treatment with oral corticosteroids (and oral itraconazole since 1998) was routinely given, but in many, symptoms recurred once corticosteroids were reduced. The child with the best lung function (patient 13; FEV₁ and FVC both 90% predicted) was a good example of this, and she also highlighted the lack of correlation between symptoms and lung function. Total serum IgE ranged from 7 to 8353 IU/ml, with a median of 306 IU/ml; five patients had levels >500 IU/ml. Serum IgG levels were normal in all but one patient who had levels just below the normal range for 2 years prior to starting IVIG (ranging from 3.2–4.9 g/l with normal age adjusted range of 5.4–16.1 g/l); the deficiency was presumed transient, as IgG levels normalised when she was older and had stopped IVIG therapy (IgA and IgM levels were normal). Prior to IVIG, baseline FEV₁ ranged from 26 to 90% predicted (median 48%), while FVC ranged from 33 to 90% predicted (median 65%).

Lung function
Analysis of the single patient who received one dose only is excluded. FEV₁ improved from a median (95% confidence interval (CI)) of 50% (39 to 61%) to 54% (48 to 66%). The difference was 7.5% (2.1 to 14.5%; NS) (fig 3). FVC improved from 65% (60 to 77%) to 83% (70 to 89%), with a difference of 13% (4 to 22%; p = 0.01) (fig 3).

Corticosteroids
Twelve patients were on regular oral prednisolone, with a median daily dose of 32.5 mg (range 2–60 mg). This represented a dose per kg body weight of 0.1–2.0 mg/kg/day (median 0.6). Oral corticosteroids were stopped completely in eight patients, reduced in three, and there was no change for one. One of the four patients who was not on oral steroids at the start, was receiving 0.5 mg/kg/day prednisolone when she died of invasive aspergillosis after her sixth dose of IVIG, while the other three remained off steroids. Taking the whole group, the median (95% CI) total daily dose per kg was reduced from 0.6 (0.3 to 1.0) to 0 (0 to 0.1), with a median (95% CI) difference of −0.6 (−1.0 to −0.1) mg/kg/day, p = 0.006 (fig 4).

All patients were on regular twice daily inhaled corticosteroids (ICS). After IVIG, they were stopped completely in one, reduced in five and remained unchanged in nine patients. Total daily dose (budesonide equivalent) was median (range) of 2000 μg (800–6000 μg), which was reduced to median (range) of 1500 μg (0–3200 μg). The median (95% CI) difference was −400 μg (−1600 to 0 μg), p<0.05 (fig 4).
Intravenous immunoglobulin for cystic fibrosis

continued on it for more than 7 years, and indeed his adult in peripheral blood was markedly reduced while IL-8/IgG ratio has been unable to wean him off this therapy, as attempts to reduce the dose or increase the dose interval result in recurrence of his Airways obstruction. For the majority of the children it was successful, with a reduction in oral corticosteroids in most and a reduction of ICS in some. This was achieved with lung function maintained and mostly improved. Overall, the regimen was well tolerated apart from in one child, who refused to carry on beyond her first dose. In some children, the improvement was maintained even after they had finished the course of treatment. This was particularly evident in the youngest child in the series, aged 3 years, whose severe recurrent wheezing illness seemed to be "switched off" by six doses of IVIG.

The anti-inflammatory mechanisms of IVIG have been recently reviewed, but the mechanisms of action specific to CF are not known. Commercially prepared immunoglobulin consists primarily of intact IgG, with traces of IgA, soluble CD4, CD8, and HLA molecules, and certain cytokines. Owing to the presence of a broad range of protective antibodies in the IVIG, one mechanism may be a reduction in viral exacerbations; one child remarked that she had had no colds since the IVIG, one mechanism may be a reduction in viral exacerbations; one child remarked that she had had no colds since the IVIG.

Table 1 Patient characteristics

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>Genotype</th>
<th>Serum IgE (IU/ml)</th>
<th>PA</th>
<th>SA</th>
<th>ABPA</th>
<th>No. of courses</th>
<th>FEV1 (%) Start</th>
<th>FVC (%) Start</th>
<th>Prednisolone mg/kg/day Start</th>
<th>ICS µg/day Stop</th>
<th>Adverse effects</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>13.8</td>
<td>ΔF508/ΔF508</td>
<td>7</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>31</td>
<td>31</td>
<td>62</td>
<td>65</td>
<td>8.5</td>
<td>0.20</td>
<td>800</td>
</tr>
<tr>
<td>2</td>
<td>15.4</td>
<td>ΔF508/ΔF508</td>
<td>271</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>9</td>
<td>48</td>
<td>69</td>
<td>60</td>
<td>84</td>
<td>1.20</td>
<td>1600</td>
</tr>
<tr>
<td>3</td>
<td>12.7</td>
<td>ΔF508/ΔF508</td>
<td>2424</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>9</td>
<td>40</td>
<td>51</td>
<td>78</td>
<td>87</td>
<td>0.60</td>
<td>2400</td>
</tr>
<tr>
<td>4</td>
<td>9.0</td>
<td>ΔF508</td>
<td>1326</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>4</td>
<td>70</td>
<td>70</td>
<td>81</td>
<td>87</td>
<td>0.80</td>
<td>3200</td>
</tr>
<tr>
<td>5</td>
<td>11.4</td>
<td>ΔF508/ΔF508</td>
<td>1739</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>7</td>
<td>29</td>
<td>38</td>
<td>33</td>
<td>52</td>
<td>1.20</td>
<td>3200</td>
</tr>
<tr>
<td>6</td>
<td>16.6</td>
<td>ΔF508/ΔF508</td>
<td>29</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>11</td>
<td>26</td>
<td>27</td>
<td>61</td>
<td>68</td>
<td>1.00</td>
<td>3000</td>
</tr>
<tr>
<td>7</td>
<td>14.6</td>
<td>ΔF508/ΔF508</td>
<td>340</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>66</td>
<td>30</td>
<td>51</td>
<td>45</td>
<td>93</td>
<td>2.00</td>
<td>3200</td>
</tr>
<tr>
<td>8</td>
<td>11.9</td>
<td>ΔF508/ΔF508</td>
<td>424</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>7</td>
<td>72</td>
<td>80</td>
<td>84</td>
<td>112</td>
<td>0</td>
<td>1000</td>
</tr>
<tr>
<td>9</td>
<td>15.5</td>
<td>ΔF508/ΔF508</td>
<td>211</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>1</td>
<td>36</td>
<td>31</td>
<td>40</td>
<td>56</td>
<td>0</td>
<td>1600</td>
</tr>
<tr>
<td>10</td>
<td>3.3</td>
<td>ΔF508/ΔF508</td>
<td>70</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>6</td>
<td>&quot;</td>
<td>&quot;</td>
<td>&quot;</td>
<td>1.50</td>
<td>0</td>
<td>1600</td>
</tr>
<tr>
<td>11</td>
<td>13.3</td>
<td>ΔF508/ΔF508</td>
<td>27</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>6</td>
<td>47</td>
<td>55</td>
<td>59</td>
<td>62</td>
<td>0.20</td>
<td>1500</td>
</tr>
<tr>
<td>12</td>
<td>13.4</td>
<td>ΔF508/ΔF508</td>
<td>2993</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>13</td>
<td>59</td>
<td>78</td>
<td>72</td>
<td>97</td>
<td>0.60</td>
<td>6000</td>
</tr>
<tr>
<td>13</td>
<td>5.3</td>
<td>ΔF508/ΔF508</td>
<td>8353</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>8</td>
<td>90</td>
<td>61</td>
<td>90</td>
<td>74</td>
<td>0.10</td>
<td>2000</td>
</tr>
<tr>
<td>14</td>
<td>13.6</td>
<td>ΔF508/ΔF508</td>
<td>201</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>6</td>
<td>51</td>
<td>50</td>
<td>65</td>
<td>72</td>
<td>0.80</td>
<td>2000</td>
</tr>
<tr>
<td>15</td>
<td>10.9</td>
<td>ΔF508/ΔF508</td>
<td>84</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>5</td>
<td>51</td>
<td>45</td>
<td>64</td>
<td>65</td>
<td>0.30</td>
<td>800</td>
</tr>
<tr>
<td>16</td>
<td>8.5</td>
<td>ΔF508/ΔF508</td>
<td>404</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>9</td>
<td>56</td>
<td>52</td>
<td>88</td>
<td>82</td>
<td>0</td>
<td>800</td>
</tr>
<tr>
<td>Median</td>
<td>13.0</td>
<td></td>
<td>306</td>
<td>Y  = 11</td>
<td>Y = 2</td>
<td>Y = 10</td>
<td>Y = 6</td>
<td>7.5</td>
<td>48</td>
<td>52</td>
<td>65</td>
<td>82</td>
<td>0.60</td>
</tr>
</tbody>
</table>

*Denotes patients still on IVIG. PA, Pseudomonas aeruginosa; SA, Staphylococcus aureus.

**Effect of IgE and ABPA**

There were no significant differences in outcomes (change in FEV1, FVC, oral or inhaled corticosteroid dose) between those with high serum IgE (>500 IU/ml) compared with low IgE (<500 IU/ml), nor between those with and without history of or current ABPA.

**Adverse reactions**

IVIG was well tolerated and the regimen acceptable to all but one of the children. The following adverse reactions were seen in one child each: headache, fever, hypotension, clinically diagnosed aseptic meningitis, and chest tightness. The child with chest tightness was sufficiently upset by her symptom that she refused further treatment with IVIG. Other recognised side effects of rashes, joint pains, and nausea were not seen. Since this review was completed, a further patient (a 16 year old girl) was started on IVIG, but 1 day after the first treatment was completed, she developed dilated pupils, severe headache, nausea, and vomiting that lasted 24–48 hours. This may have been a delayed aseptic meningitis or possibly caused by the formation of antigen–antibody complexes.

**DISCUSSION**

This series describes 16 children who received monthly infusions of IVIG in an attempt to control symptoms of severe CF lung disease and reduce their corticosteroid usage. In the index case, it has been so successful that he has continued on it for more than 7 years, and indeed his adult clinic has been unable to wean him off this therapy, as attempts to reduce the dose or increase the dose interval result in recurrence of his Airways obstruction. For the majority of the children it was successful, with a reduction in oral corticosteroids in most and a reduction of ICS in some. This was achieved with lung function maintained and mostly improved. Overall, the regimen was well tolerated apart from in one child, who refused to carry on beyond her first dose. In some children, the improvement was maintained even after they had finished the course of treatment. This was particularly evident in the youngest child in the series, aged 3 years, whose severe recurrent wheezing illness seemed to be "switched off" by six doses of IVIG.

The anti-inflammatory mechanisms of IVIG have been recently reviewed, but the mechanisms of action specific to CF are not known. Commercially prepared immunoglobulin consists primarily of intact IgG, with traces of IgA, soluble CD4, CD8, and HLA molecules, and certain cytokines. Owing to the presence of a broad range of protective antibodies in the IVIG, one mechanism may be a reduction in viral exacerbations; one child remarked that she had had no colds during the winter apart from when she missed a dose of IVIG. Interleukin-8 (IL-8), the potent neutrophil chemo-attractant, is known to play a critical part in CF lung inflammation. In a small study of high dose IVIG given to two patients with severe asthma, it was shown that free IL-8 in peripheral blood was markedly reduced while IL-8/IgG complexes were increased. IVIG may contain autoantibodies
against cytokines such as IL-8, which neutralise their biological effect, and binding of IL-8 to IgG would be likely to benefit patients with CF as well. There is some evidence that IVIG may modify the effect of *P. aeruginosa*. It has been suggested that it contains antibodies to *Pseudomonas* lipopolysaccharides and endotoxin. In theory, these anti-*Pseudomonas* antibodies may enhance killing of this organism and decrease immune complex formation, which has been implicated in lung destruction. In addition, in vitro work has shown that adding intact human IgG to CF alveolar macrophages leads to improved phagocytosis and intracellular killing of *Pseudomonas*. *Pseudomonas* specific hyperimmunoglobulin has been used as a form of passive immunotherapy in CF patients who were all chronically infected with *P. aeruginosa*. In an uncontrolled open study of 10 adults, a single dose was given during infective exacerbations. There was an improvement in lung function, an increase in anti-*P. aeruginosa* lipopolysaccharide IgG for eight immunotypes, an increase in serum anti-*P. aeruginosa* opsonic activity, and a decrease in sputum *P. aeruginosa* density.
Finally, a double blind placebo controlled study examined the effect of low dose IVIG (0.1 mg/kg) infused on three successive days in 16 CF patients undergoing intravenous antibiotic treatment for an infective exacerbation. The patients were aged over 12 years, had mild to moderate disease, and were all chronically infected with P. aeruginosa. There was a significant increase in lung function in the IVIG group (not sustained at 6 weeks) but no difference in either length of hospital stay, chest x ray, or Shwachman scores. Use of IVIG as an anti-inflammatory agent in CF began after initial reports of success in steroid dependent asthmatic patients. Three small open label studies found that IVIG infusions led to a reduction in oral steroid use in asthmatic children aged over 6 years.11-14 Unfortunately, subsequent controlled trials were conflicting and failed to show conclusive benefit.15-17 One study of 31 child and adolescent asthematics given four doses of 1 g/kg over 8 weeks showed no benefit in lung function, bronchial hyper-reactivity, or symptom scores, although there was a trend to fewer days with upper respiratory tract infections.15 More encouragingly, a study of 16 CF patients undergoing intravenous infusions led to a reduction in oral steroid use in asthmatic children aged over 6 years.31 31 4 Unfortunately, subsequent results of a proper randomised controlled trial or even a Cochrane systematic review. While we do not disagree with this worthy sentiment, realistically it is extremely unlikely that such a trial will ever happen. The patient group that would need to be studied is so diverse and (fortunately) scarce, that identification of a sufficient number of suitable patients to fit inclusion criteria would be impossible. Furthermore, the ethics of administering monthly intravenous placebo is highly questionable, especially in children such as these who are severely affected. Although there are other alternatives of success in this group of children,22 we would recommend that an n = 1 trial of IVIG in carefully selected patients with severe obstructive CF lung disease is worth considering, as for some it may lead to significant benefit.

**Authors’ affiliations**

I M Balfour-Lynn, U Mohan, A Bush, M Rosenthal, Department of Paediatric Respiratory Medicine, Royal Brompton & Harefield NHS Trust, Sydney Street, London, UK

Presented at the British Thoracic Society Winter Meeting 2000

**REFERENCES**